Clinical Trials on Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)

Total 1112 results

Shanghai Children's Medical Center
Chinese University of Hong Kong; Nanfang Hospital of Southern Medical University and other collaborators

Recruiting

TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Relapsed Pediatric AML | Relapsed Pediatric ALL | Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)

China
Equillium
Biocon Limited

Recruiting

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Graft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHD

United States, Korea, Republic of, Germany, Israel, Spain, Belgium, Italy, Australia, France, Canada, Portugal, New Zealand
Equillium
Biocon Limited

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD (EQUATE)

GVHD | GVHD, Acute | aGVHD | Acute-graft-versus-host Disease

United States
Nationwide Children's Hospital

Terminated

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Graft Versus Host Disease | Acute GVH Disease | Steroid Refractory GVHD

United States
Massachusetts General Hospital
American Cancer Society, Inc.

Completed

FMT In High-Risk Acute GVHD After ALLO HCT

Hematopoietic Cell Transplantation | Acute Graft-Versus-Host Disease (Gvhd) Grade | Fecal Microbiota Transplant

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids (MTX-aGVHD)

Stem Cell Transplant Complications | GVHD, Acute | GVH - Graft Versus Host Reaction | Allogeneic Disease

France
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

GVHD | Graft-versus-host-disease | GVHD, Acute

United States
Mesoblast, Inc.
Quintiles, Inc.

Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Grade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease

United States
Henry Ford Health System

Recruiting

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

GVHD,Acute

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

GVHD,Acute

China
John Levine

Completed

Itacitinib for Low Risk GVHD

GVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-disease

United States
University of Salamanca

Recruiting

Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)

GVHD, Chronic | GVHD,Acute

Spain
Children's Hospital Medical Center, Cincinnati

Terminated

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Graft Versus Host Disease (GVHD) | Diagnoses That Require Stem Cell Transplant

United States
Incyte Corporation

Completed

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Graft-versus-host Disease (GVHD)

United States
Incyte Corporation

Completed

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Graft-versus-host Disease (GVHD)

United States, Spain, Belgium, France, Italy, Korea, Republic of, Finland, United Kingdom, Germany, Israel, Switzerland, Austria, Australia, Czechia, Greece, New Zealand, Poland, Portugal, Taiwan
Incyte Corporation

Completed

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Graft-versus-host Disease (GVHD)

United States
MaaT Pharma

Recruiting

MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (ARES)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

Spain, France, Germany, Austria, Belgium, Italy
MaaT Pharma

Available

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

France
Columbia University
Incyte Corporation

Terminated

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Vs Host Disease | Steroid Refractory GVHD

United States
Washington University School of Medicine

Recruiting

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Chronic GVHD | Acute Graft-versus-host Disease | Chronic Graft-versus-host Disease | Acute GVHD

United States
Regimmune Corporation

Completed

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Prevention of aGVHD

United States
Anhui Provincial Hospital

Recruiting

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)

China
Leland Metheny

Withdrawn

Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease

aGVHD

China
Assistance Publique - Hôpitaux de Paris

Unknown

Biomarkers for Acute Graft-versus-host Disease (PLASMA-INCA)

Acute GVH Disease

France
Northwell Health

Withdrawn

MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease

Acute GVH Disease

United States
R.P.Herrmann
Royal Perth Hospital

Unknown

Mesenchymal Stromal Cells for Acute Graft Versus Host Disease

Acute GVH Disease

Australia
ReAlta Life Sciences, Inc.

Not yet recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA)

Steroid Refractory GVHD
CSL Behring
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Graft Versus Host Disease (GVHD)

United States
Incyte Corporation

Approved for marketing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Graft-versus-host Disease (GVHD)
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Incyte Corporation

Approved for marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Graft-versus-host Disease (GVHD)

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Graft Versus Host Disease (GVHD)

United States
M.D. Anderson Cancer Center

Completed

Feasibility Study of Collecting Multicenter Chronic GVHD Data

Graft-Versus-Host Disease

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Chronic GVHD

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

Graft Versus Host Disease | GVHD

United States
The Korean Society of Hematopoietic Stem Cell Transplantation
Hoffmann-La Roche

Unknown

Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Steroid-Refractory Chronic GVHD

Korea, Republic of
Affiliated Hospital to Academy of Military Medical...

Unknown

Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease

Acute GVH Disease

China
Shanghai Jiao Tong University School of Medicine
Shanghai Clinical Research Center

Not yet recruiting

Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis

GVHD

China
NYU Langone Health

Completed

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

GVHD

United States
VectivBio AG

Active, not recruiting

Proof-of-concept Trial of Apraglutide in GVHD

GVHD

United States, Spain, Germany, Portugal
Samsung Medical Center
Medipost Co Ltd.

Unknown

Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease (GVHD-MSC)

Graft-Versus-Host Disease | GVHD | Disorder Related to Transplantation | Allogeneic Hematopoietic Transplant

Korea, Republic of
Massachusetts General Hospital
Novartis

Terminated

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

Graft Versus Host Disease

United States
Massachusetts Eye and Ear Infirmary

Completed

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

Ocular GVHD

United States
Hadassah Medical Organization

Completed

Alefacept for Chronic Graft Versus Host Disease

Resistant Chronic GVHD

Israel
Radboud University Medical Center

Completed

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease (MATADOR)

Allogeneic Stem Cell Transplant | Acute Myeloid Leucaemia | Myelo Dysplastic Syndrome | Acute Graft Versus Host Disease Grade II-IV

Netherlands, Belgium
Jules Bordet Institute
Macopharma; Belgian Hematological Society

Recruiting

Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Refractory Chronic Graft Versus Host Disease (cGVHD)

Belgium
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Graft Versus Host Disease | GVHD

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Graft-Versus-Host Disease (GVHD) Acute on Chronic

United States
Shanghai Children's Medical Center
BioMérieux

Unknown

Clinical Evaluation of the Application of the FilmArray GI Panel in Post-HSCT Diarrhea Patients

GVHD - Graft-Versus-Host Disease

Clinical Trials on Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations